SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer. We are a “start-up with a head start,” having launched in 2017 with a portfolio of promising clinical-stage therapies and with strong financial backing from a group of leading life science investors and pharmaceutical industry partners.
Our lead pipeline programs are for rare oncology indications: a gamma secretase inhibitor is in a Phase 3 clinical trial for the treatment of desmoid tumors, and we expect to initiate a Phase 2b study with our MEK 1/2 inhibitor for the treatment of neurofibromatosis type 1 patients with plexiform neurofibromas in 2019. There are currently no therapies approved for the treatment of patients diagnosed with either of these devastating tumor types. We are also advancing our MEK inhibitor as a backbone for rational combination therapies in solid tumors through partnerships with other biopharmaceutical companies.
SpringWorks has created a channel for evaluating additional assets to license from Pfizer and is also actively pursuing new licensing and partnership opportunities with other innovators. We pioneer efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new therapies to underserved patients.
We have assembled an experienced management team led by accomplished drug developers. Our team of SpringWorkers is focused on exceptional execution and is driven to deliver life-changing medicines for the patients who are counting on us. At SpringWorks, we ignite the power of promising science to unleash new possibilities for patients.